Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Colorectal Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 104 articles: HTML format Text format

Single Articles

June 2018
1. TAN RYC, Camat MD, Ng M, Lim TH, et al
   HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients.
   Ann Oncol. 2018 Jun 3. pii: 5001837. doi: 10.1093.
   PubMed     Text format    
   
   
   May 2018
2. MORANO F, Corallo S, Niger M, Barault L, et al
   Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
   Ann Oncol. 2018 May 31. pii: 5026003. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
3. TRENSZ P, Calvel L, Kurtz JE
   The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
   Ann Oncol. 2018 May 22. pii: 5001429. doi: 10.1093.
   PubMed     Text format    
   
   
   April 2018
4. APARICIO T, Bouche O, Taieb J, Maillard E, et al
   Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
   Ann Oncol. 2018 Apr 30. pii: 4990353. doi: 10.1093.
   PubMed     Text format    
   
   
   
5. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
   Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
   Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
6. CREMOLINI C, Antoniotti C, Lonardi S, Bergamo F, et al
   Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.
   Ann Oncol. 2018 Apr 20. pii: 4979452. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
7. SANTOS C, Sanz-Pamplona R, Salazar R
   RET-fusions: a novel paradigm in colorectal cancer.
   Ann Oncol. 2018 Apr 10. pii: 4965879. doi: 10.1093.
   PubMed     Text format    
   
   
   
8. SIENA S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, et al
   Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
   Ann Oncol. 2018 Apr 6. pii: 4962457. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
9. MASUISHI T, Taniguchi H, Sugiyama K, Kato K, et al
   Eribulin in BRAF V600E mutant metastatic colorectal cancer: Case series and potential rationale.
   Ann Oncol. 2018 Apr 4. pii: 4959907. doi: 10.1093.
   PubMed     Text format    
   
   
   March 2018
10. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2018 with focus on colorectal cancer.
    Ann Oncol. 2018 Mar 19. pii: 4935197. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
11. MONTAGUT C, Tsui DW, Diaz LA Jr.
    Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?
    Ann Oncol. 2018 Mar 14. pii: 4937227. doi: 10.1093.
    PubMed     Text format    
    
    
    
12. SMEBY J, Sveen A, Merok MA, Danielsen SA, et al
    CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Ann Oncol. 2018 Mar 5. pii: 4922418. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    February 2018
13. ARNOLD D, Prager GW, Quintela A, Stein A, et al
    Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Ann Oncol. 2018 Feb 14. pii: 4857261. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
14. BACHET JB, Bouche O, Taieb J, Dubreuil O, et al
    RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
    Ann Oncol. 2018 Feb 9. pii: 4846852. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. CARR PR, Alwers E, Bienert S, Weberpals J, et al
    Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses.
    Ann Oncol. 2018 Feb 9. pii: 4846850. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
16. SOBRERO A, Grothey A, Iveson T, Labianca R, et al
    The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer?
    Ann Oncol. 2018 Feb 9. pii: 4846853. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    January 2018
17. SOBHANI I, Itti E, Luciani A, Baumgaertner I, et al
    Colorectal Cancer (CRC) Monitoring by Six-Monthly 18FDG-PET/CT: An Open-Label Multicentre Randomised Trial.
    Ann Oncol. 2018 Jan 22. pii: 4819113. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
18. CARMELIET P, Li X, Treps L, Conradi LC, et al
    RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients.
    Ann Oncol. 2018 Jan 19. pii: 4817343. doi: 10.1093.
    PubMed     Text format    
    
    
    
19. PARK JH, McMillan DC
    Outcome in colorectal cancer - tumour, stroma and so much more.
    Ann Oncol. 2018 Jan 8. pii: 4792956. doi: 10.1093.
    PubMed     Text format    
    
    
    
20. DELL'AQUILA E, Cremolini C, Zeppola T, Lonardi S, et al
    Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
    Ann Oncol. 2018 Jan 8. pii: 4793700. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    December 2017
21. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
22. DANIELSEN HE, Hveem TS, Domingo E, Pradhan M, et al
    Prognostic markers for colorectal cancer; estimating ploidy and stroma.
    Ann Oncol. 2017 Dec 27. pii: 4779924. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
23. YAMADA Y, Denda T, Gamoh M, Iwanaga I, et al
    S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial.
    Ann Oncol. 2017 Dec 27. pii: 4779925. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
24. GONG J, Tian J, Lou J, Wang X, et al
    A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267.
    Ann Oncol. 2017 Dec 18. pii: 4756051. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
25. ORDONEZ-ME JM, Walter V, Schottker B, Jenab M, et al
    Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium.
    Ann Oncol. 2017 Dec 13. pii: 4735153. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
26. TABERNERO J, Hozak RR, Yoshino T, Cohn AL, et al
    Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study.
    Ann Oncol. 2017 Dec 7. pii: 4708229. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    November 2017
27. YOSHINO T, Arnold D, Taniguchi H, Pentheroudakis G, et al
    Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
    Ann Oncol. 2017 Nov 16. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
28. ABAD A, Martinez-Balibrea E, Vieitez JM, Orduna VA, et al
    Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
29. DIENSTMANN R, Guinney J
    Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al.
    Ann Oncol. 2017;28:2889-2890.
    PubMed     Text format    
    
    
    October 2017
30. OVERMAN M, Adam L, Raghav K, Wang J, et al
    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
31. TARAZONA N, Cervantes A
    Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format    
    
    
    
32. SCIALLERO S, Battistuzzi L, Varesco L
    Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer.
    Ann Oncol. 2017;28:2620-2621.
    PubMed     Text format    
    
    
    
33. CASADEI GARDINI A, Valgiusti M, Passardi A, Frassineti GL, et al
    Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?
    Ann Oncol. 2017;28:2620.
    PubMed     Text format    
    
    
    September 2017
34. APARICIO T, Bouche O, Taieb J, Maillard E, et al
    Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results.
    Ann Oncol. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
35. CREMOLINI C, Morano F, Moretto R, Berenato R, et al
    Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
36. GARCIA-FONCILLAS J, Alba E, Aranda E, Diaz-Rubio E, et al
    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
37. SIENA S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, et al
    Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer.
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
38. SOBRERO A, Damiani A
    Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.
    Ann Oncol. 2017;28:2043-2044.
    PubMed     Text format    
    
    
    
39. WEI Q, Ye Z, Zhong X, Li L, et al
    Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.
    Ann Oncol. 2017;28:2135-2141.
    PubMed     Text format     Abstract available
    
    
    
40. GOEY KKH, Elias SG, van Tinteren H, Lacle MM, et al
    Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Ann Oncol. 2017;28:2128-2134.
    PubMed     Text format     Abstract available
    
    
    August 2017
41. NORMANNO N, Esposito Abate R, Lambiase M, Forgione L, et al
    RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Ann Oncol. 2017 Aug 7. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
42. BERGER MD, Stintzing S, Heinemann V, Yang D, et al
    Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
43. WHITE NM, Maher CA
    The potential use of lncRNAs found in the 8q24 region as biomarkers for colon cancer.
    Ann Oncol. 2017;28:1688-1689.
    PubMed     Text format    
    
    
    
44. OZAWA T, Matsuyama T, Toiyama Y, Takahashi N, et al
    CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 'gene desert', serve as important prognostic biomarkers in colorectal cancer.
    Ann Oncol. 2017;28:1882-1888.
    PubMed     Text format     Abstract available
    
    
    July 2017
45. SANZ-GARCIA E, Argiles G, Elez E, Tabernero J, et al
    BRAF mutant Colorectal Cancer: prognosis, treatment and new perspectives.
    Ann Oncol. 2017 Jul 24. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    June 2017
46. SCHLESINGER S, Aleksandrova K, Abar L, Vieria AR, et al
    Adult weight gain and colorectal adenomas-a systematic review and meta-analysis.
    Ann Oncol. 2017;28:1217-1229.
    PubMed     Text format     Abstract available
    
    
    May 2017
47. WILLIS JA, Vilar E
    Refining Prognosis in Early-Stage Colorectal Cancer: One or multiple genes at a time?
    Ann Oncol. 2017 May 26. doi: 10.1093.
    PubMed     Text format    
    
    
    
48. SUNAKAWA Y, Tsuji A, Fujii M, Ichikawa W, et al
    No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
    Ann Oncol. 2017 May 5. doi: 10.1093.
    PubMed     Text format    
    
    
    
49. DIENSTMANN R, Mason MJ, Sinicrope FA, Phipps AI, et al
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Ann Oncol. 2017;28:1023-1031.
    PubMed     Text format     Abstract available
    
    
    
50. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Ann Oncol. 2017;28:1015-1022.
    PubMed     Text format     Abstract available
    
    
    
51. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
    Ann Oncol. 2017;28:958-968.
    PubMed     Text format     Abstract available
    
    
    
52. OTT PA, Piha-Paul SA, Munster P, Pishvaian MJ, et al
    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
    Ann Oncol. 2017;28:1036-1041.
    PubMed     Text format     Abstract available
    
    
    April 2017
53. ROHR UP, Herrmann P, Ilm K, Zhang H, et al
    Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
54. BOECKX N, Koukakis R, Op de Beeck K, Rolfo C, et al
    Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
    Ann Oncol. 2017 Apr 25. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
55. BONNETAIN F, Borg C, Adams RR, Ajani JA, et al
    How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.
    Ann Oncol. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
56. VIDAL J, Muinelo L, Dalmases A, Jones F, et al
    Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
    Ann Oncol. 2017 Apr 13. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
57. ARNOLD D, Lueza B, Douillard JY, Peeters M, et al
    Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
58. VIEIRA AR, Abar L, Chan D, Vingeliene S, et al
    Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR Continuous Update Project.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
59. KWAKMAN JJ, Simkens LH, van Rooijen JM, van de Wouw AJ, et al
    Randomised phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
    Ann Oncol. 2017 Apr 5. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
60. FONT R, Espinas JA, Layos L, Martinez Villacampa M, et al
    Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?
    Ann Oncol. 2017;28:831-835.
    PubMed     Text format     Abstract available
    
    
    
61. BUDHATHOKI S, Iwasaki M, Yamaji T, Yamamoto H, et al
    Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population.
    Ann Oncol. 2017;28:818-823.
    PubMed     Text format     Abstract available
    
    
    March 2017
62. MA B, King AD, Leung L, Wang K, et al
    Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer - a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
    Ann Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
63. ROSPO G, Corti G, Crisafulli G, Novara L, et al
    Tracking colorectal cancer evolution in time and space.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format    
    
    
    
64. SIRAVEGNA G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al
    Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
65. GRASSELLI J, Elez E, Caratu G, Matito J, et al
    Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
66. FUCHS MA, Yuan C, Sato K, Niedzwiecki D, et al
    Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance).
    Ann Oncol. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
67. ROMBOUTS AJM, Hugen N, Elferink MAG, Feuth T, et al
    Incidence of second tumors after treatment with or without radiation for rectal cancer.
    Ann Oncol. 2017;28:535-540.
    PubMed     Text format     Abstract available
    
    
    February 2017
68. PILATI C, Taieb J, Balogoun R, Marisa L, et al
    CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Ann Oncol. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
69. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format    
    
    
    
70. LOTE H, Spiteri I, Ermini L, Vatsiou A, et al
    Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
71. SANTINI D, Vincenzi B, Addeo R, Garufi C, et al
    Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format    
    
    
    
72. DIENSTMANN R, Mason MJ, Sinicrope FA, Phipps AI, et al
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    
    
    
    
73. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    
    
    
    
74. PATEL UB, Brown G, Machado I, Santos-Cores J, et al
    MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
    Ann Oncol. 2017;28:344-353.
    PubMed     Text format     Abstract available
    
    
    
75. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Text format     Abstract available
    
    
    
76. GLYNNE-JONES R
    Adding extra dimensions in rectal cancer theory.
    Ann Oncol. 2017;28:198-200.
    PubMed     Text format    
    
    
    January 2017
77. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and Prognostication in Stage III Colon Cancer: Future Perspectives for Adjuvant Therapy.
    Ann Oncol. 2017 Jan 27. pii: mdx030. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
78. POWELL MA
    Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard.
    Ann Oncol. 2017;28:9-10.
    PubMed     Text format    
    
    
    December 2016
79. TAIEB J, Balogoun R, Le Malicot K, Tabernero J, et al
    Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Ann Oncol. 2016 Dec 28. pii: mdw687. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
80. SCHUURHUIZEN CS, Braamse AM, Konings IR, Sprangers MA, et al
    Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review.
    Ann Oncol. 2016 Dec 19. pii: mdw617. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
81. SELIGMANN JF, Fisher D, Smith CG, Richman SD, et al
    Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    November 2016
82. PIETRANTONIO F, Miceli R, Rimassa L, Lonardi S, et al
    Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
83. SWETS M, Breugom AJ, Gelderblom H, van de Velde CJ, et al
    Should rectal cancer located 10-15cm from the anal verge be defined as colon cancer.
    Ann Oncol. 2016.
    PubMed     Text format    
    
    
    October 2016
84. QUIDDE J, Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al
    Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
85. STELLOO E, Jansen AM, Osse EM, Nout RA, et al
    Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
86. MOORE M, Gill S, Asmis T, Berry S, et al
    Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
87. DEENEN MJ, Meulendijks D
    Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format    
    
    
    September 2016
88. 
    appendix 5: Metastatic colorectal cancer (2): eUpdate published online August 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    PubMed     Text format    
    
    
    
89. 
    appendix 4: Metastatic colorectal cancer (1): eUpdate published online September 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    PubMed     Text format    
    
    
    August 2016
90. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
91. IMAOKA H, Toiyama Y, Fujikawa H, Hiro J, et al
    Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    July 2016
92. VARDY JL, Dhillon HM, Pond GR, Renton C, et al
    Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
93. MEI Z, Duan C, Li C, Cui L, et al
    Prognostic role of tumor PIK3CAmutation in colorectal cancer: a systematic review and meta-analysis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
94. VAN CUTSEM E, Cervantes A, Adam R, Sobrero A, et al
    ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    June 2016
95. MODEST DP, Ricard I, Heinemann V, Hegewisch-Becker S, et al
    Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants - pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
96. SOBRERO A
    A tribute to biologics in advanced colorectal cancer treatment.
    Ann Oncol. 2016.
    PubMed     Text format    
    
    
    May 2016
97. MICHL M, Stintzing S, Fischer von Weikersthal L, Decker T, et al
    CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
98. REN HG, Luu HN, Cai H, Xiang YB, et al
    Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
99. LUO HY, Xu RH
    Reply to "Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients" by C. Cremolini et al.
    Ann Oncol. 2016.
    PubMed     Text format    
    
    
    
100. YAMAZAKI K, Nagase M, Tamagawa H, Ueda S, et al
     Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
     Ann Oncol. 2016.
     PubMed     Text format     Abstract available
     
     
     
101. CREMOLINI C, Moretto R, Masi G, Falcone A, et al
     Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients.
     Ann Oncol. 2016.
     PubMed     Text format    
     
     
     
102. SARTORE-BIANCHI A, Loupakis F, Argiles G, Prager GW, et al
     Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the lab.
     Ann Oncol. 2016.
     PubMed     Text format     Abstract available
     
     
     February 2016
103. ROSATI G, Ambrosini G, Barni S, Andreoni B, et al
     A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma.
     Ann Oncol. 2016;27:274-80.
     PubMed     Text format     Abstract available
     
     
     December 2014
104. SCHOFFSKI P, Besse B, Gauler T, de Jonge MJ, et al
     Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell l
     Ann Oncol. 2014.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: